Highlights PMD Device Solutions AB

Equities

PMDS

SE0021513645

Delayed Nasdaq Stockholm Other stock markets 15:53:53 16/05/2024 BST			5-day change	1st Jan Change
7.5 ^SEK	-5.66%		-10.71%	-29.58%

05-02	PMD Device Solutions Agrees on Head of Terms to License the Coala-Life Technology	CI
04-11	PMD Device Solutions AB (OM:PMDS) acquired Coala Life Inc from Coala-Life Group AB for SEK 3.6 million.	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PMD Device Solutions Agrees on Head of Terms to License the Coala-Life Technology	05-02	CI
PMD Device Solutions AB (OM:PMDS) acquired Coala Life Inc from Coala-Life Group AB for SEK 3.6 million.	04-10	CI
PMD Device Solutions to Purchase Coala-Life Group's US Unit	04-09	MT
PMD Device Solutions AB (OM:PMDS) intends to acquire Coala Life Inc. from Coala-Life Group AB.	04-08	CI
PMD Device Solutions AB Begins Preparation for First German Hospital Pilot	03-25	CI
PMD Device Solutions to Complete Reverse Stock Split; Shares Soar	01-29	MT
Pmd Device Solutions AB completed the acquisition of Promore Pharma AB (OM:PROMO) in a reverse merger transaction.	12-28	CI
Promore Pharma to Buy PMD Device Solutions via Reverse Acquisition; Stock Skyrockets	11-29	MT
Pmd Device Solutions AB intends to acquire Promore Pharma AB (OM:PROMO) in a reverse merger transaction for approximately SEK 130 million.	11-28	CI
Promore Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-28	CI
Promore Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	30/08/23	CI
Promore Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23/05/23	CI
Promore Pharma Reports Outcome from Clinical Phase II Study with Ensereptide	20/04/23	CI
Promore Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	28/02/23	CI
Promore Pharma Reaches the Clean File Milestone in its Phase II Clinical Trial with Ensereptide	27/02/23	CI
Promore Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	29/11/22	CI
Promore Pharma Provides an Update on the Phase II Clinical Trial with Ensereptide	01/11/22	CI
Promore Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	30/08/22	CI
Promore Pharma Up 15% After Receiving EU Patent For Drug	10/08/22	MT
Promore Pharma AB Receives A Granted Patent in the European Union for the Use of the Candidate Drug Ropocamptide (LL-37) for the Treatment of Chronic Wounds	10/08/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights PMD Device Solutions AB

Equities

PMDS

SE0021513645

Highlights

Filters